FTC v. Enforma
This article was originally published in The Tan Sheet
Executive Summary
Supplement firm must remove from market all Fat Trapper Plus, Exercise in a Bottle products carrying certain weight-loss claims under a stipulated preliminary injunction entered Dec. 9 by Los Angeles federal Judge Spencer Letts. Court subsequently denied Enforma's request for stay of the injunction pending appeal. Enforma was hit with a similar preliminary injunction for its Chitozyme, Acceleron weight-loss products in October (1"The Tan Sheet" Nov. 4, 2002, In Brief). Civil contempt hearing is slated for Jan. 21 barring a settlement between Enforma, FTC...
You may also be interested in...
FTC v. Enforma
Supplement firm preliminarily enjoined from making certain weight-loss claims for Chitozyme and Acceleron under Los Angeles federal Judge Spencer Letts' Oct. 30 order. FTC says Enforma must recall, repackage and relabel products while also ensuring vendors are in compliance. Enforma is seeking stay of the preliminary injunction pending appeal. FTC now is expected to seek similar injunctive relief for Enforma's Fat Trapper Plus and Exercise In A Bottle. Court's order stems from FTC's July 23 civil contempt motion (1"The Tan Sheet" Aug. 5, 2002, p. 5)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.